On September 13th, the four-day BIOHK2023 Hong Kong International Biotechnology Forum kicked off at the Hong Kong Convention and Exhibition Center, Supported by the China Association for Science and Technology, the Ministry of Science and Technology, and the Hong Kong Special Administrative Region Government. BIOHK2023 stands as a preeminent international biotechnology event initiated by the esteemed Hong Kong Biotechnology Association, boasting its status as one of Asia's largest conferences in this field. This gathering convenes numerous distinguished experts and academicians across diverse disciplines, including Nobel laureate Dr. Bruce Beutler, Academician Gao Fu from Chinese Academy of Sciences, Academician Han Jisheng, Dr. Wang Yu from former National Center for Disease Control and Prevention, alongside various international medical policy makers, industry elites, academia representatives, and investment professionals to deliberate upon research accomplishments in different domains while fostering professional growth through innovative thinking exchange and successful experience sharing. Dr. Du Tao, Chairman of Evergreen Therapeutics, and Dr. Li Changqing, Chief Medical Officer were invited to attend this conference as guest speakers.
The conference theme, "Biotech Kaleidoscope," aims to explore the boundless possibilities of biopharmaceuticals through cutting-edge technologies. As an international event, the discussion surrounding the successful entry of Chinese innovative drugs into the global market remains highly significant. Dr. Du Tao, a seasoned FDA evaluation expert with extensive experience in technology transfer, delivered a keynote speech titled "Overseas Transfer Strategies for Chinese Innovative Drugs." Dr. Du emphasized that license-out has become an indispensable fourth capability in China's current strategy for expanding overseas markets for innovative drugs, and selecting appropriate clinical indications based on global clinical needs is crucial for achieving success. Accelerating the utilization of new technologies such as AI to enhance development efficiency and obtaining endorsement from international regulatory authorities can further augment the likelihood of successful expansion into foreign markets. During the subsequent panel discussion, Dr. Du shared his insights and experiences with experts, receiving unanimous recognition from attendees at the event.
Dr. Tom Du is giving a keynote speech
Dr. Tom Du (positioned on the far right) actively participates in discussions with esteemed experts during the roundtable session, including Dr. Men Yuxin, CMO of Haichang Biology; Dr. Li Ning, CEO of Junshi Biosciences; and Mr. Tang Ming, General Manager of International Business Department at Yunnan Baiyao."
Artificial intelligence (AI) has been widely applied as a crucial tool for drug development, particularly in the stage of drug discovery. However, currently there are only a limited number of companies in China that apply AI technology to the clinical stage. As a trailblazer in leveraging AI to empower clinical research, Evergreen has pioneered precise patient selection, biomarker screening, optimization of patient enrollment criteria, and global clinical trial design by innovatively utilizing AI technology to transcend traditional research constraints and enhance the efficiency of drug clinical development. Dr. Li Changqing, CMO of Evergreen Therapeutics, delivered a keynote speech titled “Improving Drug Development Efficiency and Success Rate through AI in Clinical Research” at the conference. Dr. Li pointed out that the application of AI is revolutionizing the paradigm of clinical research; current clinical studies are gradually transitioning from early-stage traditional hypothesis-driven approaches to data-driven methods involving AI and machine learning techniques. In the future, with continuous iteration and maturation of generative AI models, it will be possible to automatically generate and validate new hypotheses by amalgamating vast amounts of data and relevant domain knowledge while providing profound data exploration capabilities. This will enable cross-domain data correlation and analysis within multiple research areas, evolving into an 'AI-scientific method' paradigm for clinical research which significantly enhances both efficiency and success rate.
Dr. Charles Lee is giving a keynote speech
Dr. Charles Lee (first from left) at the Global Innovative Drug Development Strategy Roundtable Forum
As an international innovative pharmaceutical company empowered by AI in clinical research, Evergreen Therapeutics has always adhered to the mission of "focusing on clinical needs and benefiting global patients". With the advantage of a diverse team comprising top international talents from various disciplines, we actively leverage artificial intelligence technology to overcome traditional challenges and persistently pursue differentiated innovation and implement a “dual-business” model operation. Currently, our company is making rapid clinical progress through the application of our self-developed AI platform for proprietary pipeline development. The invitation for two leaders from Evergreen to share their successful experiences as guest speakers reflects the industry's attention to and recognition of Evergreen's innovative capabilities.
